Anke Biotechnology released its 2026 interim report. During the reporting period, total operating revenue was 1.098 billion yuan, down 15.04% from the same period last year. Net profit attributable to the parent company was 332 million yuan, down 9.33% year on year. Net cash inflow from operating activities was 272 million yuan, down 13.88% year on year. The company's latest asset-liability ratio was 13.94%, gross margin was 75.82%, return on equity was 7.80%, and diluted earnings per share was 0.20 yuan. The number of shareholders was 66,200, and the top ten shareholders held 40.14% of the total share capital.
Anhui Anke BioTech GroupInterim net profit fell 9.33% year on year, revenue down 15.04%, and operating cash flow down 13.88%.
